Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: Meta-analyses of 20 randomized controlled trials and subgroup analyses

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Liang, Wenhua ^a   Wu, Xuan ^a   Hong, Shaodong ^a   Zhang, Yaxiong ^a   Kang, Shiyang ^a   Fang, Wenfeng ^a   Qin, Tao ^a   Huang, Yan ^a   Zhao, Hongyun ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; MOTESANIB; NINTEDANIB; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; DRUG DOSE COMPARISON; DRUG TARGETING; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; ENZYMOLOGY; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84908032810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109757     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in OncologyTM. Non-Small Cell Lung Cancer. V 2.2010. http://www.nccn.org/professionals/physician gls/PDF/nscl.pdf. Accessed April 8; 2010.
3. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008; (Suppl. 1): 5-13.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801): 249-57.
6. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. Paclitaxel carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 2006; 355: 2542-2550.
7. Ivy SP, Wick JY, Kaufman BM. An overview of small molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009; 6: 569-579.
8. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24(9): 2371-6.
9. Wozniak A. Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. Crit Rev Oncol Hematol. 2012 May; 82(2): 200-12.
10. Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, et al. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2013; 69(2): 151-9.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
14. Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol 2010; 5(3): 354-60.
15. Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012; 30(17): 2070-8.
16. Spigel DR, Burris 3rd HA, Greco FA, Shipley DL, Friedman EK, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29(18): 2582-9.
17. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28(11): 1835-42.
18. Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012; 30(25): 3084-92.
19. Wang Y, Wang L, Liu Y, Yu S, Zhang X, et al. Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer. [Article in Chinese] Zhongguo Fei Ai Za Zhi 2011; 14(3): 239-44.
20. Molina JR, Dy GK, Foster NR, Allen Ziegler KL, Adjei A, et al. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. Journal of Clinical Oncology 2011; 29 [Abstract 7513].
21. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010; 28(1): 49-55.
22. Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, et al. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as firstline therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. J Thorac Oncol 2013; 8(1): 79-88.
23. Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, et al. A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR.29. J Clin Oncol 2012; 30 S:abstr 7511.
24. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25(27): 4270-7.
25. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11(7): 619-26.
26. de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011; 29(8): 1067-74.
27. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008; 26(33): 5407-15.
28. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29(8): 1059-66.
29. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009; 27(15): 2523-9.
30. Lee JS, Hirsh V, Park K, Qin S, Blajman CR, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30(10): 1114-21.
31. Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012; 30(23): 2829-36.
32. Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, et al. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2011; 22(9): 2057-67.
33. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small- cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15(2): 143-55.
34. Cesca M, Bizzaro F, Zucchetti M, Giavazzi R. Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents. Front Oncol 2013; 3: 259.
35. Johnson DH1, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22(11): 2184-91.
36. Hellmann MD1, Chaft JE, Rusch V, Ginsberg MS, Finley DJ, et al. Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. Cancer Chemother Pharmacol 2013; 72(2): 453-61.